Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study.

摘要: There is no standard first-line chemotherapy for advanced gastric cancer with severe peritoneal metastasis. Although fluoropyrimidine often used, its efficacy limited, and it remains unclear whether combination therapy platinum improves clinical outcomes. This retrospective study involved patients at six Japanese academic hospitals between 2010 2016. Patients metastasis were included if they had massive ascites and/or inadequate oral intake requiring intravenous nutritional support. We then compared the safety of monotherapy those fluoropyrimidine/platinum therapy. Compared group (n = 64), (n = 65) worse general health (more elderly age, performance status > 2, having both intake). Both overall survival (9.0 vs 5.0 months, p < 0.01) progression-free (4.3 2.3 months, significantly longer in group, significance remained after adjusting prognostic variables (hazard ratios 0.47 0.41, respectively; p < 0.01). Improvements also greater group. neutropenia (grade ≥ 3) occurred more frequently therapy, treatments this tolerable. Combination might be effective than was tolerable